Our Clinical Pipeline
Currently, four Inhibrx programs are in ongoing Phase 1 clinical trials: three for the treatment of various cancers, and one for Alpha-1 Antitrypsin Deficiency (AATD).
The Candidates
Preclinical
Phase 1
Phase 2
Phase 3
Oncology
INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40 currently being evaluated in patients with locally advanced or metastatic solid tumors. Signaling through OX40 provides co-stimulation that promotes T-cell expansion, enhanced effector function and memory cell formation, and prevents activation-induced cell death.
Learn more clinicaltrials.gov
INBRX-109
Our Tetravalent DR5 Agonist
Oncology
INBRX-109 is a precisely engineered tetravalent sdAb-based therapeutic candidate that agonizes DR5 to induce tumor selective programmed cell death.
Learn more clinicaltrials.gov
INBRX-105
Our PD-L1 x 4-1BB Tetravalent Conditional Agonist
Oncology
INBRX-105 is a tetravalent sdAb-based therapeutic candidate currently being evaluated in patients with programmed death ligand 1 (PD-L1) expressing tumors, including those refractory to, or relapsed from, approved checkpoint inhibitor therapies. INBRX-105 is designed to agonize 4-1BB selectively in the presence of PD-L1.
Learn more clinicaltrials.gov
INBRX-101
Our Recombinant Alpha-1 Anti- trypsin Fc-Fusion Protein (AAT-Fc)
Orphan / Respiratory
INBRX-101 is a recombinant human AAT-Fc fusion protein therapeutic candidate currently being evaluated for the treatment of AATD. Early clinical data has demonstrated a promising pharmacokinetic profile that we believe supports a dosing schedule of every three weeks to achieve continuous normal AAT serum concentrations, a significant improvement from patients’ current regimen.
Learn more clinicaltrials.gov
Near-term Clinical Milestones
1. INBRX-109 (DR5) Initiation of chondrosarcoma registration-enabling trial
2. INBRX-106 (OX40 / Keytruda dose escalation data
3. INBRX-101 (AAT) Initial Phase 1 data
4. INBRX-105 (PD-L1 x 41BB) Keytruda dose-escalation data
5. INBRX-109 (DR5) Initial pancreatic and mesothelioma combination study data
6. INBRX-101 (AAT) Additional Phase 1 data
7. INBRX-109 (DR5) Ewing sarcoma combination study data
8. INBRX-106 (OX40) / Keytruda dose-expansion cohort data
9. INBRX-105 (PD-L1 x 41BB) Keytruda dose-expansion cohort data
